GERN Stock Summary and Trading Ideas (Geron | NASDAQ:GERN)

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Geron trades on the NASDAQ stock market under the symbol GERN.

As of March 13, 2026, GERN stock price declined to $1.58 with 13,481,770 million shares trading.

GERN has a beta of 1.41, meaning it tends to be more sensitive to market movements. GERN has a correlation of 0.20 to the broad based SPY ETF.

GERN has a market cap of $1.01 billion. This is considered a Small Cap stock.

Last quarter Geron reported $48 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.01.

In the last 3 years, GERN traded as high as $5.34 and as low as $1.04.

The top ETF exchange traded funds that GERN belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

GERN has underperformed the market in the last year with a price return of -5.4% while the SPY ETF gained +21.4%. However, in the short term, GERN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +16.2% vs -2.6% return in SPY. But in the last 2 weeks, GERN shares have been beat by the market, returning -6.0% compared to an SPY return of -3.5%.

GERN support price is $1.50 and resistance is $1.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GERN shares will trade within this expected range on the day.